AO 2004-23
U.S. OncologySummary
SSF's solicitation of subsidiaries' restricted classes.
Documents
Final opinion August 12, 2004
| Date | Name | Document type |
|---|---|---|
| 08/12/2004 | AO 2004-23 | Final Opinion |
| 08/12/2004 | Vote | Votes |
| 08/09/2004 | Draft AO (OGC), Agenda Document 04-71 | Draft Documents |
| 08/06/2004 | Supplement to Request | AO Request, Supplemental Material, and Extensions of Time |
| 07/09/2004 | Supplement to Request | AO Request, Supplemental Material, and Extensions of Time |
| 06/28/2004 | Supplement to Request | AO Request, Supplemental Material, and Extensions of Time |
| 06/10/2004 | Request by U.S. Oncology, Inc. Good Government Fund | AO Request, Supplemental Material, and Extensions of Time |
Entities
| Role | Name | Type |
|---|---|---|
| Requestor | U.S. Oncology, Inc. Good Government Committee | Separate segregated fund |
| Requestor | U.S. Oncology, Inc. | Corporation (including LLCs electing corporate status) |
| Counsel/Representative | ShawPittman LLP | Law Firm |
| Counsel/Representative | Mr. Thomas J. Spulak | Individual |
| Counsel/Representative | Dr. Fred N. Ekery MD | Individual |
| Counsel/Representative | Dr. Leonard A. Kosova MD | Individual |
| Counsel/Representative | Dr. Mark C. Myron MD | Individual |